Table 2 Candida species and initial empiric antifungal medication received by exposure status
From: Statins in Candidemia: clinical outcomes from a matched cohort study
| Â | Patients on Statins, N (%) | Patients Not on Statins, N (%) | p-value |
|---|---|---|---|
Candida Sp. | Â | Â | Â |
Candida albicans | 6 (40%) | 11 (37%) | 0.3 |
Candida glabrata | 4 (27%) | 11 (37%) | 0.5 |
Candida parapsilosis | 3 (20%) | 4 (13%) | 0.57 |
Candida tropicalis | 1 (7%) | 4 (13%) | 0.5 |
Mixed Candida* | 2 (13%) | 0 | 0.2 |
Antifungal Therapy | Â | Â | Â |
Amphotericin B | 1 (7%) | 1 (3%) | 1.0 |
echinocandin | 7 (47%) | 12 (40%) | 0.75 |
fluconazole | 7 (47%) | 17 (57%) | 0.54 |